Question: article in the new England journal of medicine italy research
Any information you can provide regarding research by Tor Vergara University of Rome and clinical trials for the drug Mongersen? It surpresses the production of Smad7 protein. How is this the same and or different to anti-tnf biologics? Thank you.
Mongersen is a very promising new drug. There are a few sites in Canada that will be participating in Phase 2 clinical trials to further evaluate this potential new therapy for IBD. Phase 2 and Phase 3 clinical trials still need to be done, so if all goes well, then it would be a few years before it is approved for use outside of clinical trials.
Mongersen is similar to anti-TNF drugs in that it leads to the suppression of inflammation pathways in the body. Many signalling pathways have been shown to be influenced by IBD. Anti-TNF drugs target the TNF-alpha pathway. Mongersen targets the TGF-beta and SMAD7 signalling pathways.